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ABSTRACT 
Background Greater trochanteric pain syndrome (GTPS) is common, resulting in significant pain and 
disability. There is no condition specific outcome score to evaluate the degree of severity of GTPS in 
or effectiveness of treatment for, patients with this condition.  
Objective To develop a reliable and valid outcome tool to measurement the severity of GTPS, so as 
to be able to evaluate treatments.   
Methods An iterative process of item generation, clarification, reduction was used to develop this 
outcome tool, the VISA-G.  The VISA-G was tested for reliability (ICC), internal consistency 
(Cronbach’s Alpha), and construct validity (correlation co-efficient) on 52 naïve participants with 
GTPS and 31 asymptomatic participants. 
Results The resultant outcome tool is consistent in style with existing tendinopathy outcome tools, 
namely the suit of VISA scores. The VISA-G was found to be have a test retest reliability of ICC2,1 (95% 
CI) of 0.827 (0.638 to 0.779). Internal consistency was high with a Cronbach’s Alpha of 0.809. 
Construct validity was demonstrated: the VISA-G measures different constructs than both the HHS 
and the ODI (Spearman Rho:0.020 and0.0205 respectively). The VISA-G did not demonstrate any 
floor or ceiling effect in symptomatic participants.  
Conclusion The VISA-G has is a reliable and valid score for measuring the severity of GTPS.   
  
2 
 
[Type text] 
 
INTRODUCTION 
Greater trochanteric pain syndrome (GTPS) is a common, chronic, disabling condition characterised 
by intermittent or continuous pain at, or around, the greater trochanter of the femur.[1  2 3] The 
condition can be debilitating enough to reduce activity and capacity for employment.[4] GTPS has a 
reported incidence of 1.8 patients per 1000 per year in primary care.[5] Prevalence rates of 23.5% in 
women at risk of knee osteoarthritis [6] and 54% in recipients of renal transplants [7] have been 
reported. These statistics likely underestimate the prevalence of GTPS as misdiagnosis of GTPS is 
common.[8-11]   
Risk factors for developing GTPS are poorly understood however female gender, older age,[1 6] 
greater adiposity,[6] back pain [4 6] and a higher femoral neck angle [12] have been associated with 
the condition. Older women are over represented in GTPS by a ratio of approximately 4:1,[5 6] with 
the reported age of diagnosis of between 45 and 63 years.[1 5 6]   
Despite the reported prevalence and disability, a condition specific patient reported outcome (PRO) 
tool has not been developed for this condition. Surrogate measures using tools designed for hip 
osteoarthritis or low back pain have been used.[1 4 13] Evaluation of the level of severity, and of the 
effectiveness of treatment across studies would be enhanced by the use of a PRO.[14 15]  
The VISA questionnaires have a consistent structure has been shown to be valid for the assessment 
of lower limb tendinopathies. The VISA-P, VISA-A and VISA-H have been widely adopted to quantify 
the disability associated with patellar, Achilles and hamstring tendinopathy respectively.[16-18] 
Additionally, their purpose is to monitor and evaluate treatment strategies for these conditions.[19] 
As GTPS is a tendinopathy involving the gluteus medius and minimus tendons,[20-24] the VISA 
questionnaire structure may be a valid to adopt for this population. The objective of this study was 
to develop a valid PRO questionnaire, based on the VISA questionnaire structure, for people with 
GTPS. The development of the VISA-G followed the Consensus-based Standards for the selection of 
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health Measurement Instruments (COSMIN) guidelines for the development and testing of health 
measurement instruments provide a methodology for the development health measurement 
tools.[25] 
METHODS 
The development of this instrument used qualitative and quantitative methods  using three steps: 
(1) item generation and format refinement, (2) item reduction, and (3) evaluation of the 
psychometric properties of the final version.[26] Existing VISA questionnaires were used to guide the 
format of the VISA-G.[16-18]   
Participants 
Participants were recruited via social and professional networks. Participants were screened for 
exclusion criteria and then provided with a comprehensive participant information sheet before 
providing written consent. Ethical approval for this study was provided by ACT health human 
research ethics committee, Australian National University human research ethics committee, Calvary 
health care ACT human research ethics committee, Deakin University human research ethics 
committee, and the Monash University human research ethics committee. 
Inclusion criteria 
GTPS participants: 
In the item generation stage of this research GTPS participants were identified by clinician as having 
trochanteric bursitis and / or gluteal tendinopathy as the primary diagnosis.  In subsequent stages 
GTPS was defined as a history of lateral hip pain,[2 3 6 20 24 27-30] pain on palpation of the greater 
trochanter,[1  2 3 20 28 29 31] and one or both of lateral hip pain with lying on the ipsilateral side,[1 
29 31 ] or during weight bearing activities or sitting.[2 11 31]  
Asymptomatic participants 
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Participants were included in the asymptomatic group if they were healthy with no current or history 
of back or hip pain requiring them to seek treatment for the condition. 
Exclusion criteria 
Participants were excluded if they had any signs or symptoms of hip OA based on Altman criteria 
[33], systemic inflammatory disease e.g. rheumatoid arthritis; lumbar spine nerve root signs; a 
history of lumbar spine or ipsilateral hip joint surgery; osteogenic disease e.g. Paget’s disease; or a 
corticosteroid injection to the ipsilateral lateral hip region in the preceding three months. 
Participants with co-morbidities that restricted their activity level more than their hip pain did – thus 
invalidating question eight (Q8), were also excluded.  
Health professional inclusion 
Physiotherapists were invited to attend two focus groups. Fifteen to 20 physiotherapists were 
present at each meeting with experience ranging from new graduate to extensive (post graduate 
musculoskeletal training and more 20 years of experience). No physiotherapist was excluded.   
One sports physician, two orthopaedic surgeons and a physician with a post graduate diploma in 
ultrasound imaging, all with an interest in the condition were involved in the item generation on a 
one-to-one discussion basis. 
Process 
Step 1 Item generation 
Item generation was undertaken using a number of methods: A literature review identified items 
noted in the literature; focus groups of physiotherapists discussed the literature review findings in 
addition to their personal observations of presentation and dysfunction of clients with GTPS; and 
semi-structured interviews of people with GTPS (N=42). The information from the literature review, 
the focus groups and the in depth interviews provided triangulation of data.[32]  These data were 
condensed into a draft questionnaire. Trial questionnaires were sent to interview participants for 
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testing of question accuracy, clarity and questionnaire design.[33] This was done in an iterative 
fashion – until no new domains were elicited. The subsequent iteration was trialled on 73 naive 
GTPS participants. These data informed the item reduction.  
Step 2 Item reduction 
Item reduction was undertaken by two experienced research physiotherapists (AF & JC). The results 
from the questionnaire were evaluated for domain generation using principal component analysis 
and scree plots, and for redundancy using Spearman Rho correlation. In this early version, ceiling 
and floor effects were tested via descriptive statistics. This process resulted in a reduction from 21 to 
seven questions. In line with the VISA questionnaire model two questions regarding level of activity 
(Q7 & Q8) were added to account for variation in tendon pain due to variation in tendon loading. [17 
18] 
Step 3 Item scaling 
As with existing VISA scores, the first six questions were scored between 0 and 10, while the 
categorisation questions (7 and 8) were scored out of 10 and 30 respectively.  
Step 4 Evaluation of psychometric properties 
The final version of the VISA-G had a visual analogue score for pain (0 = worst pain, 10 = no pain), 
four questions related to pain (Questions 2,3, 4 and 6), one question related to difficulty with 
moving after sitting (Question 5) and two activity related questions (Questions 7 and 8). This version 
of the VISA-G (Attachment A) was tested on 52 naïve participants with GTPS; 49 women (mean age 
(SD)) 58.9 (13.64), and 3 men (53.0, SD 15.13). In addition 31 asymptomatic participants were 
tested:  24 women (57.4 (5.59) and 7 men (58.4 (5.22). Three asymptomatic participants did not 
specify their gender or age on the questionnaire.  
Internal consistency: Internal consistency is the degree to which the items in questionnaire are 
interrelated.[25] A principal component factor analysis was performed on the individual items to 
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determine their structural validity. A Cronbach’s alpha and 95% confidence intervals was calculated 
for each item and a score above 0.70 was taken as a sufficient level of homogeneity among the 
items.[34] 
Test retest reliability: An intraclass correlation coefficient (ICC) was used to compare VISA-G scores 
of 26 GTPS participants who completed the PROs one week apart.  
Face, content and construct validity: The VISA-G was developed following wide consolation with 
symptomatic participants, and health professionals. Content validity was assessed via assessment 
against the Harris Hip Score (HHS) and the Oswestry Disablity Index (ODI) – two scores that have 
previously been used in GTPS research and no reference standard exists to test the VISA-G against.[1 
4 35] Construct validity was calculated to determine if the VISA-G correlated with the Harris Hip 
Score (HHS) and the Oswestry Disability Index (ODI) scores using a Spearman’s Rank correlation 
coefficient.[1 4] . 
Sample size calculation: Using the pain measure as the measure to determine the sample size, 
assuming a minimally significant difference of 1.5 points on the VAS [36], a power of 90, and an 
alpha of 0.05, the expected sample size required is 38. Using the larger pain difference of two points, 
and the same parameters, results in a sample size of 20 for each group.  
Floor and Ceiling effects: Floor and ceiling effects were examined by evaluating the distribution of 
total scores and determining if more than 15% of the participants achieved either the lowest or the 
highest score. 
Data analysis 
Statistical analysis for data reduction was undertaken using Stata IC 10.1 (Statacorp, USA). Statistical 
analysis for stability and groups differences was undertaken using SPSS Statistics (version 19, IBM 
SPSS Inc. Chicago, IL, USA). 
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Eighty three complete questionnaires were used in the analysis, no imputation was used for missing 
items.  
Item reduction: Multivariate techniques including factor analysis, bi-plots and Spearman rho 
correlation coefficients were employed. Using Factor Analysis results, two researchers reviewed the 
eigenvalues and loading factor for each question in VISA-Gv1. Biplots were used to examine the 
variance of each question, a higher variance was assumed to be associated with lower specificity of 
the domain. Spearman rho correlation co-efficient in combination with the factor analysis was used 
to identify items that appeared to measure the same construct, thus identifying redundancy and 
allowing question deletion. For example the level of discomfort associated with pushing a shopping 
trolley will depend upon how full the trolley is, likewise, the discomfort associated with getting in or 
out of a car will depend on which leg is affected and whether you are the driver or the passenger. 
We retained the five questions that covered 95% of the variance in the questionnaire. Thus we 
reduced the questionnaire from 22 questions to six (the five plus the pain VAS). To account for 
variation in tendon pain due to variation in tendon loading,[17 18] questions regarding level of 
activity (similar to VISA-A and VISA-P) was added to the final version (questions 7 and 8). 
Results 
Participants with GTPS had scores associated with higher levels of pain and dysfunction than the 
asymptomatic participants (Table 1).   
Table 1: Result from the GTPS and asymptomatic participants for the VISA-G, Harris Hip Score and 
the Oswestry Disablity Index.   
Instrument GTPS participants 
(Mean, SD) 
N = 52 
Asymptomatic participants  
(Mean, SD) 
N = 31 
T-Test 
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VISA-G 47.00(13.35) 99.84(0.64) <0.001 
HHS 66.50(13.48) 89.32(4.38) <0.001 
ODI 11.33(7.85) 0.26(0.77) <0.001 
Note: VISA-G = VISA score for GTPS; HHS = Harris Hip Score; ODI = Oswestry Disability Index 
High scores for VISA-G and HHS indicate less disability. Lower scores for the ODI indicate less 
disability.  
Psychometric Testing 
Test-retest reliability: The VISA-G demonstrated a high level of reliability: ICC2,1 (95% CI) of 0.827 
(0.638 to 0.779). 
Internal consistency: Initial analysis resulted in a Cronbach’s Alpha (95% CI) of 0.52 (0.29-0.71) for 
the eight items. Post hoc stepwise item elimination yielded a Cronbach’s Alpha range of 0.377 to 
0.809.  Deletion of question 8 resulted in the biggest change to the Cronbach’s Alpha; increasing it to 
0.809. The principal components analysis revealed that questions one to seven contributed evenly to 
the outcome of the score, with a range of mean (SD) of between 6.43 (3.84) and 8.30 (2.48). 
Question eight had a mean (SD) of 14.64 (13.28).  
Validity 
Face validity: The extensive item generation, logical item reduction, and the rigorous trialling over 
time with naive populations of symptomatic and asymptomatic people confers face validity.   
Construct validity: Spearman correlation coefficient analysis illustrates the correlations between the 
VISA-G, HHS and ODI (Table 2). In participants with GTPS, the VISA-G did not correlate with either 
the HHS or the ODI, while in the asymptomatic group the VISA-G did correlate with the HHS, but not 
the ODI. 
Table 2. Construct Validity (Spearman Rho's correlation co-efficient).  
 Group VISA-G HHS ODI 
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VISA G GTPS 1.000 0.020 0.205 
 Asymptomatic 1.000 0.410* -0.300 
HHS GTPS 0.020 1.000 -0.778† 
 Asymptomatic 0.410* 1.000 -0.149 
ODI GTPS 0.205 -0.778† 1.000 
 Asymptomatic -0.300 -0.149 1.000 
* p = 0.022; † p ≤ 0.001.  
VISA-G = VISA score for GTPS; HHS = Harris Hip Score; ODI = Oswestry Disability Index 
Content Validity: The development process for the VISA-G, including people with GTPS and two 
forms of clinicians, suggests that the questionnaire has content validity.  
Floor and ceiling effects: No floor or ceiling effects were identified in the GTPS group with less than 
15% of participants in the GTPS groups scoring the minimum or maximum values. Not surprisingly, 
94% of the asymptomatic group scored the maximum value.  
Discussion 
The objective of this study was to develop a reliable and valid PRO questionnaire to assess the 
severity of, and efficacy of treatment for, GTPS. We have demonstrated that the VISA-G has good 
reliability – both internally and on a test-retest basis. The VISA-G has been shown to have content 
and construct validity. Concurrent criterion validity has been demonstrated, although not predictive 
criterion validity, thus meeting the majority of the COSMIN standards. Further research is needed to 
complete the process of demonstrating responsiveness and minimal clinical significance.  
The validity of the VISA-G was assessed with the rigorous and recursive nature of the initial item 
generation and thorough item identification. While some of the questions overlap with the Harris 
Hip Score,[37] the scores from HHS and the VISA-G did not correlate, suggesting that the two scores 
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are measuring different constructs. The high internal consistency further supports this, as does the 
result that people with GTPS scored higher on the VISA-G score than the control group. 
The VISA-G has internal consistency for the questions that evaluated the GTPS construct (Q 1 – 6).  
The remaining questions modulate the effect of activity on the total score, consistent with the 
standard VISA format.[17 18 38] The HHS, ODI and the non-arthritic hip score [39] do not have such 
influential questions.  
The activity level question (Q 8) in existing VISA scores focus on sport and training activities. Our 
item generation did not identify sport as a major activity of people with GTPS. Rather, walking and 
shopping were more common activities impacted on by GTPS. We amended this question in the 
VISA-G to weight bearing activities. This move away from sport related activities reflects the 
different age group that is represented in population with GTPS, as opposed to the younger and 
more active population with patellar tendinopathy particularly,[18] Achilles tendinopathy [17] and 
hamstring tendinopathy.[38] 
The VISA-G is a measure of severity of GTPS and is not diagnostic, diagnosis should be clinical with a 
history and examination, including using the FABER test.[40] Patients with GTPS are likely to have 
comorbidities such as pain generated from the back and hip joint and the  VISA-G score will likely be 
influenced by these. Interestingly, GTPS participants with non-specific low back pain (without 
referral) were included in this study, yet the correlation with the ODI in this population was not 
significant. This suggests that the VISA-G is responsive to GTPS independently of back pain 
symptoms. This is noteworthy when considering the study that treated GTPS in people diagnosed 
with back pain, and found an improvement in the ODI score.[13]   
The VISA-G is modelled on existing VISA tendon outcome tools.[17 18 38] The VISA-G follows the 
standard VISA format, importantly including measures of activity level (Questions 7 and 8). It is 
expected that in line with other VISA tools Q1 – 6 are likely to be very responsive to change, but Q7 
and 8 likely to be slower – thus re-testing should only be done on a monthly or bi-monthly period.   
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Limitations 
A limitation of this study was that the GTPS participants represent people seeking conservative 
physiotherapy treatment. GTPS can be treated with corticosteroid injections and tendon 
reconstructions,[41 42] thus the VISA-G has not been tested a cross the full spectrum of a population 
with GTPS. In addition, testing of responsiveness and establishing minimum clinical significance was 
not possible with a cross-sectional study design.   
Conclusion 
This study found that the VISA-G is reliable and valid. It will be a useful tool for evaluating the 
severity of disability in, and the effectiveness of treatment for people with GTPS.  
 
WHAT ARE THE NEW FINDINGS 
1. A Valid and reliable tool for measuring the severity of GTPS.  
2. VISA-G provides a tool for measuring the effectiveness of 
treatment for GTPS in both clinical and research settings. 
 
HOW MIGHT THIS IMPACT OF CLINICAL PRACTICE IN THE NEAR FUTURE 
• The VISA-G provides clinicians with an object method of measuring changes in 
people with GTPS, thus informing ongoing treatment.  
• The VISA-G provides researchers with an object method of measuring changes in 
people with GTPS, thus making the results of research more convincing.  
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